Jubilant Life Sciences gains 8.53% on USFDA drug approval

Jubilant Life Sciences rose over 8% on BSE during opening trade on Monday after the company received USFDA approval for its RUBY-FILL- Rubidium 82 Generator and elution system. 

At 9.38 am, the shares of Jubilant Life Sciences trading at Rs 665.90 per share,up 8.53%. 

"The product is expected to be launched in the current quarter (third quarter of financial year 2017) under the company’s registered brand name RUBY-FILL for which the current estimated US market size is US$76mn and has a potential to grow up to US$250mn annually in the next five years," It said.